logo
Concern over weight gain after ‘skinny jabs'

Concern over weight gain after ‘skinny jabs'

Powys County Times17 hours ago
Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming off the drugs should be given support to help prevent them piling on the pounds again.
Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said.
The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain.
The guidance is for people who are offered the treatments through the NHS.
An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment.
Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years.
The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed.
It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'.
This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients.
'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice.
'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.
'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.'
Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix.
Little swaps can make tasty, healthy changes.
For lots of tips and support to eat better visit: https://t.co/T56V7G8FkJ pic.twitter.com/K42yzvkF2V
— NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025
'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits.
'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support.
'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term.
'This standard ensures healthcare services are equipped to provide that essential ongoing support.'
Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight.
'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable.
'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.'
Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk.
'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice.
'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS issues vaccination warning for pregnant women over dangerous virus currently surging in Australia
NHS issues vaccination warning for pregnant women over dangerous virus currently surging in Australia

The Independent

time5 minutes ago

  • The Independent

NHS issues vaccination warning for pregnant women over dangerous virus currently surging in Australia

Expectant mothers and people over 75 are being urged to get vaccinated against a potentially deadly virus following a record number of cases in Australia. Health chiefs say the Australian winter often predicts how viruses will spread in the UK, and already this year cases of respiratory syncytial virus (RSV) have steadily risen in many areas. The virus, which is a common cause of coughs and colds, may also cause a chest infection called bronchiolitis. Some people have a high risk of becoming seriously ill with it, including babies and adults over 75. According to NHS England, RSV is a leading cause of infant deaths worldwide and a main cause of children being taken into hospital. Last winter, almost 7,000 bed days in England were taken up by children with RSV. NHS England is encouraging pregnant women to get a jab that protects against RSV so their babies are protected after birth. Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Yusra Osman says that when her son, Zakariya, was three months old, he developed bronchiolitis from the virus. He had a fever and was gasping for breath. The 34-year-old, from north London, said: 'Everything was a blur, but I remember his chest was caving in and out and he was really struggling to catch his breath.' Nurses found her son's oxygen levels were dangerously low. Ms Osman, a student midwife, said: 'That was one of those things you don't want to hear as a mum. He was crying, and we kept trying to put an oxygen mask on, but he was fighting to get it off and didn't want to be touched.' Zakariya, who is now seven, needed oxygen and a feeding tube in hospital. 'It's a mum's worst nightmare. Had the RSV vaccine been available then, I'd definitely have had it,' Ms Osman said. The RSV vaccine was offered to pregnant women in England for the first time last September and health officials say it has since helped to protect more than 300,000 mothers and babies. Pregnant mothers from 28 weeks onwards are eligible, as are adults aged 75 to 79. In the coming weeks, NHS England is set to invite more than a million people to have a jab, before the season for infections, which starts in October. Greta Hayward, consultant midwife at the UK Health Security Agency, said babies born in late summer or the autumn are most likely to be admitted to hospital with the virus. 'Hundreds of babies attend emergency departments each day for bronchiolitis through most of November and December,' she said.

OpenAI changes ChatGPT to stop it telling people to break up with partners
OpenAI changes ChatGPT to stop it telling people to break up with partners

The Guardian

time35 minutes ago

  • The Guardian

OpenAI changes ChatGPT to stop it telling people to break up with partners

ChatGPT will not tell people to break up with their partner and will encourage users to take breaks from long chatbot sessions, under new changes to the artificial intelligence tool. OpenAI, ChatGPT's developer, said the chatbot would stop giving definitive answers to personal challenges and would instead help people mull over issues such as breakups. 'When you ask something like: 'Should I break up with my boyfriend?' ChatGPT shouldn't give you an answer. It should help you think it through – asking questions, weighing pros and cons,' said OpenAI. The US company said new ChatGPT behaviour for dealing with 'high-stakes personal decisions' would be rolling out soon. OpenAI admitted this year that an update to ChatGPT had made the groundbreaking chatbot too agreeable and altered its tone. In one reported interaction before the change, ChatGPT congratulated a user for 'standing up for yourself' when they claimed they had stopped taking their medication and left their family – who were supposedly 'responsible' for radio signals emanating from the walls. In the blog post OpenAI admitted there had been instances where its advanced 4o model had not recognised signs of delusion or emotional dependency – amid concerns that chatbots are worsening people's mental health crises. The company said it was developing tools to detect signs of mental or emotional distress so ChatGPT can direct people to 'evidence-based' resources for help. A recent study by NHS doctors in the UK warned that AI programs could amplify delusional or grandiose content in users vulnerable to psychosis. The study, which has not been peer reviewed, said this could be due in part to the models being designed to 'maximise engagement and affirmation'. The study added that even if some individuals benefitted from AI interactions, there was a concern the tools could 'blur reality boundaries and disrupt self-regulation'. OpenAI added that from this week it would send 'gentle reminders' to take a screen break to users engaging in long chatbot sessions, similar to screen-time features deployed by social media companies. OpenAI said it had convened an advisory group of experts in mental health, youth development and human-computer-interaction to guide its approach. The company has worked with more than 90 doctors including psychiatrists and paediatricians to build frameworks for evaluating 'complex, multi-turn' chatbot conversations. 'We hold ourselves to one test: if someone we love turned to ChatGPT for support, would we feel reassured? Getting to an unequivocal 'yes' is our work,' said the blog post. The ChatGPT alterations were announced amid speculation that a more powerful version of the chatbot is imminent. On Sunday Sam Altman, OpenAI's chief executive, shared a screenshot of what appeared to be the company's latest AI model, GPT-5.

Thousands of patients miss out on weight loss jab due to NHS ‘postcode lottery'
Thousands of patients miss out on weight loss jab due to NHS ‘postcode lottery'

The Independent

timean hour ago

  • The Independent

Thousands of patients miss out on weight loss jab due to NHS ‘postcode lottery'

Thousands of obese patients are missing out on a key weight loss jab due to a 'postcode lottery' of provision in the NHS, according to a report. Mounjaro, dubbed the 'King Kong' of weight loss medicine, was supposed to be available through GP surgeries from 23 June under an agreement between NHS England and NICE. But just eight out of 42 NHS Integrated Care Boards (ICBs) in England were able to provide treatment to patients, according to Sky News, who obtained the data using a Freedom of Information request. Many other ICBs were reportedly unable to confirm when treatment would be available. Dr Jonathan Hazlehurst, an endocrinologist and obesity physician at University Hospitals Birmingham, said patients were 'set up for failure' and have been treated unfairly. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair. That's what the current system is doing,' he told the broadcaster. NICE said in December that the NHS should offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazlehurst claims NHS England has only provided funding for just over 22,000 patients. The Independent has approached NHS England for comment. A spokesperson told Sky News that NHS England had "fully supported the rollout" of Mounjaro. "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services,' they said. It comes after NICE warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. The new 'quality standard' from NICE says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store